Publications – Service A

RHUMATOLOGIE / SERVICE – A

Les dernières publications :

Tumor necrosis factor-a (TNF-a) inhibitors are the most widely used first-line biologic therapy for the treatment of rheumatoid arthritis. Much has been written on the concern that TNF-a inhibitors may increase the risk of  malignancy, infections, and other serious adverse events.

Fibrosis arises from excessive deposition of extracellular matrix components and results in scarring of various tissues. It is a hallmark of systemic sclerosis (SSc), which is a prototypical fibrotic disease affecting both the skin and many internal organs such as the lungs and gastrointestinal tract.

Systemic sclerosis (SSc) is a chronic systemic disease with a complex pathogenesis. The disease is characterized by early vascular alterations and activation of the immune system, with autoimmune features preceding the deposition of extracellular matrix, leading to systemic fibrosis.

Osteoporosis (OP) and fractures are major causes of morbidity in subjects with rheumatic inflammatory diseases. The etiology of bone loss in rheumatic diseases is multifactorial, involving age, disability, low body mass index (BMI), longstanding disease, disease-related systemic inflammation, and longterm glucocorticoid (GC) exposure.

Regular exercise is encouraged among healthy people to prevent death and disease from cardiovascular disease, osteoporosis, anxiety, and depression. Thus, people with rheumatoid arthritis (RA) who have increased susceptibility for these comorbid conditions may benefit from regular exercise and may be encouraged to exercise.

Systemic sclerosis (SSc) is characterised by major vascular involvement. Pulmonary arterial hypertension (PAH) is currently an important challenge in SSc and given the severity of this condition and the poor understanding of its risk factors and pathogenesis, there is an urgent need to identify novel risk factors for the development of SSc–PAH.

Juvenile idiopathic arthritis (JIA) is a heterogeneous group of 7 diseases classified by the International League of Associations for Rheumatology (ILAR). Two forms with polyarticular onset were identified: rheumatoid factor (RF)-positive and RF-negative polyarticular JIA (pJIA).